1461088586-2c8d245d-56ca-43a4-b953-04141d60ecb1

1. An illuminable safety umbrella, comprising:
a center pole having an upper end and an opposite hand-gripping end;
an umbrella cover mounted to the upper end and capable of selective closure and opening;
a housing mounted to the hand-gripping end of the center pole;
the housing including an internal chamber, an opening and a plurality of annular inner threads adjacent the opening;
the chamber sized to receive therein at least one battery;
an onoff switch mounted to the housing and electrically interconnected to the battery;
a loop and cap member detachably securable to the housing;
the loop and cap member having a threaded portion for engagement to the annular inner threads of the housing, and a loop portion;
the loop portion including an aperture for attachment to an article of clothing;
a mounting member mounted to the upper end of the center pole and above the umbrella cover;
a removably securable casing seated upon the mounting member;
an illumination means enclosed within the casing; and
a plurality of electrical wires extending from the internal chamber to the mounting member for electrically interconnecting the battery to the illumination means so that selectively disposing the onoff switch to the on position causes the illumination means to light up thereby making the individual holding the umbrella more visible.
2. The illuminable safety umbrella of claim 1 wherein the illumination means is a LED bulb.
3. The illuminable safety umbrella of claim 2 wherein the securement of the loop and cap member to the housing encloses and contains the battery within the internal chamber of the housing.

The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.

1. An inverter gate board divided into a low-voltage region and a high-voltage region, the inverter gate board comprising:
a plurality of drive circuits surface-mounted between the low-voltage region and the high-voltage region and each having a single main power source (SMPS) controller; and
a plurality of transformers surface-mounted between the low-voltage region and the high-voltage region so as to supply a transformed voltage to each of the plurality of drive circuits, respectively.
2. The inverter gate board according to claim 1, wherein the plurality of drive circuits supply a gate power to individual power modules.
3. The inverter gate board according to claim 2, further comprising a controller surface-mounted to the high-voltage region and communicating with the plurality of drive circuits and a control board, wherein the plurality of drive circuits receive information from the individual power modules and transmit the information to the controller.
4. The inverter gate board according to claim 3, further comprising an optical coupler to insulate the controller from the low-voltage region.

1461088576-4644da1c-3910-4851-9048-5fc4b6af7499

What is claimed is:

1. A method of treatment of benign prostatic hyperplasia comprising the steps of:
(a) orally administering an initial dosage of about 40 mg of 13-cis-retinoic acid daily for an initial treatment period from about ten days to about twenty days, and
(b) thereafter orally administering a sustaining dosage of about 40 mg of 13-cis-retinoic acid about every five to seven days in a sustaining period.
2. The method of claim 1 wherein said sustaining period is about one year.
3. The method of claim 1 wherein said initial treatment period is about fourteen days.
4. The method of claim 1 wherein said 13-cis-retinoic acid is in a form selected from the group consisting of powder, pill, capsule, tablet, and liquid.
5. The method of claim 4 wherein said liquids comprise 13-cis-retinoic acid in a pharmaceutical media selected from the group consisting of water, glycol, oil, alcohol, and syrup.
6. A method of reduction of a level of a prostate specific antigen (PSA) of benign prostate conditions comprising the steps of:
(a) orally administering an initial dosage of about 40 mg of 13-cis-retinoic acid daily for an initial treatment period from about ten days to about twenty days, and
(b) thereafter orally administering a sustaining dosage of about 40 mg of 13-cis-retinoic acid about every five to seven days in a sustaining period.
7. The method of claim 6 wherein said sustaining period is about one year.
8. The method of claim 6 wherein said initial treatment period is about fourteen days.
9. The method of claim 6 wherein said 13-cis-retinoic acid is in a form selected from the group consisting of powder, pill, capsule, tablet, and liquid.
10. The method of claim 9 wherein said liquids comprise 13-cis-retinoic acid in a pharmaceutical media selected from the group consisting of water, glycol, oil, alcohol, and syrup.

The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.

1-30. (canceled)
31. A plate glass which comprises, as represented by mole percentage based on oxides, from 62 to 68% of SiO2, from 6 to 12% of Al2O3, from 7 to 13% of MgO, from 9 to 15% of Na2O, from 0 to 7% of K2O, and from 0 to 1% of CaO, wherein the difference obtained by subtracting the content of Al2O3 from the total content of Na2O and K2O is less than 10%, and ZrO2 is contained in an amount of at most 0.8%.
32. The plate glass according to claim 31, wherein the content of CaO is from 0 to 0.5%.
33. The plate glass according to claim 31, wherein ZrO2 is contained in an amount of at most 0.5%.
34. The plate glass according to claim 31 or 32, wherein the content of Na2O is from 9 to 12.5%.
35. The plate glass according to claim 31 or 32, wherein the content of Na2O is from 12 to 15%.
36. The plate glass according to claim 31 or 32, which contains no B2O3.
37. The plate glass according to claim 31 or 32, wherein the content of Al2O3 is from 7 to 10%
38. The plate glass according to claim 31 or 32, wherein the total content of CaO, SrO and BaO is at most 1%.
39. The plate glass according to claim 31 or 32, wherein the total content of SiO2 and Al2O3 is more than 72% and at most 76%.
40. The plate glass according to claim 31 or 32, wherein the content of MgO is from 8 to 11%.
41. The plate glass according to claim 31 or 32, wherein the content of SiO2 is from 63 to 65%.